Teemu Murtola

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Prostatectomy 42%
3. Hydroxymethylglutaryl-CoA Reductase Inhibitors 32%
4. Androgens 18%
5. Finland 17%
6. Prostate 15%
7. Hypoglycemic Agents 14%
8. Cohort Studies 13%
9. Survival 11%
10. Cholesterol 11%
11. Neoplasms 11%
12. Atorvastatin 11%
13. Early Detection of Cancer 10%
14. Prostate-Specific Antigen 10%
15. Population 10%
16. Mortality 10%
17. Pharmaceutical Preparations 9%
18. Randomized Controlled Trials 8%
19. Erectile Dysfunction 8%
20. Castration 8%
21. Metformin 7%
22. Anti-Inflammatory Agents 7%
23. Drug Users 7%
24. Precision Medicine 7%
25. Antihypertensive Agents 7%
26. Recurrence 6%
27. Incidence 6%
28. Breast Neoplasms 6%
29. Registries 6%
30. Visual Analog Scale 6%
31. menthyl 3-(2-pyridylsulfinyl)acrylate 6%
32. Urinary Incontinence 6%
33. Adaptive Clinical Trials 5%
34. Phenomics 5%
35. Therapeutics 5%
36. MicroRNAs 5%
37. Fitness Trackers 5%
38. alfuzosin 5%
39. Case-Control Studies 5%
40. Simvastatin 5%
41. 5-alpha Reductase Inhibitors 5%
42. oxidized low density lipoprotein 5%
43. Serum 5%
44. Aspirin 5%